| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Syndax Pharmaceuticals, Inc. (SNDX) has 3 insiders with recent SEC Form 4 filings, including 4 buys and 2 sells. SNDX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 484.8K | $9.37M | -6,847 | |
| CFO | 139.3K | $2.69M | -1,177 | |
| Dir | 0 | - | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Mar 21, 2019 | Meyers Michael L. | SVP, Chief Medical Officer | Buy | 1,104 | $4.92 | $5,436.48 | +8.3% | |
| Oct 30, 2018 | Meyers Michael L. | SVP, Chief Medical Officer | Buy | 200 | $4.79 | $958.00 | +9.1% | |
| Apr 3, 2018 | Ordentlich Peter66 | Chief Scientific Officer | Sale+OE | 7,500 | $15.00 | $112,500.00 | -100% | |
| May 17, 2017 | Ordentlich Peter66 | Chief Scientific Officer | Sale+OE | 5,000 | $15.00 | $75,000.00 | -100% | |
| Mar 8, 2016 | Royston Ivor | Director | Buy | 150,000 | $12.00 | $1,800,000.00 | +25.0% |